EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...

Correspondent Jon Wertheim revisits 60 Minutes' coverage of former mobile giant Nokia and discusses potential risks for the ...

Novo Nordisk chief financial officer Karsten Munk Knudsen said on Wednesday the company was aware of reports of 10 deaths and ...

while in the United States all doses of Ozempic are currently available. Nevertheless, the shortage is still a strong hint of the extremely high demand and Novo Nordisk might be able to grow ...

Both Ozempic and Wegovy are forms of semaglutide, a GLP-1 agonist drug manufactured by Novo Nordisk ... demand for semaglutide within the United States exceeds the available supply.

“Honestly, I’m quite alarmed by what we see in the U.S. now,” Novo Nordisk President and CEO Lars Fruergaard ... the demand ...

The Stoxx Europe 600 Index swelled 1.5% to 517.07. Related NewsInflation Rate YoY for Oct in United States is 2.6%, higher ...

COPENHAGEN (Reuters) - Novo Nordisk is lifting curbs on prescriptions of its weight-loss drug Wegovy in the United States and is increasing supply in that market, its CEO said on Wednesday.

“This Republican team is united behind President Trump’s agenda, and our work starts today,” Thune said in a statement after he was elected. Still, in his first post-election news conference, he ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

More than two years after a historic Supreme Court decision ended the national right to an abortion, some states are fighting ...

Belgium and the United States - onto Novo Nordisk for $11 billion. The sites will then by fully used by Novo Nordisk for ...